Laura E. Niklason - 08 Dec 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
President, CEO and Director, Director, 10%+ Owner
Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
08 Dec 2022
Net transactions value
$0
Form type
4
Filing time
12 Dec 2022, 15:11:17 UTC
Previous filing
19 Sep 2022
Next filing
15 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +444,500 $0.000000 444,500 08 Dec 2022 Common Stock 444,500 $3.07 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026.